Next Article in Journal
Acknowledgement to Reviewers of Pharmaceuticals in 2016
Next Article in Special Issue
Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor
Previous Article in Journal / Special Issue
CK2—An Emerging Target for Neurological and Psychiatric Disorders
Open AccessArticle

Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining

Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Westfälische Wilhelms-Universität Münster, Corrensstr. 48, 48149 Münster, Germany
Faculty of Pharmacy, Damascus University, Damascus, P.O. Box 9411, Syria
Université de Lyon, Université Claude Bernard Lyon 1, Faculté de Pharmacie—ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453—INSERM US7, 8 Avenue Rockefeller, F-69373 Lyon CEDEX 8, France
School of Pharmacy, Faculty of Health Sciences, University of Eastern, 70211 Kuopio, Finland
University Hospital Tübingen, Department of Internal Medicine VIII, Otfried-Müller-Straβe 10, 72076 Tübingen, Germany
Author to whom correspondence should be addressed.
Academic Editor: Lorenzo A. Pinna
Pharmaceuticals 2017, 10(1), 8;
Received: 13 December 2016 / Revised: 3 January 2017 / Accepted: 4 January 2017 / Published: 9 January 2017
Protein kinase CK2, initially designated as casein kinase 2, is an ubiquitously expressed serine/threonine kinase. This enzyme, implicated in many cellular processes, is highly expressed and active in many tumor cells. A large number of compounds has been developed as inhibitors comprising different backbones. Beside others, structures with an indeno[1,2-b]indole scaffold turned out to be potent new leads. With the aim of developing new inhibitors of human protein kinase CK2, we report here on the generation of common feature pharmacophore model to further explain the binding requirements for human CK2 inhibitors. Nine common chemical features of indeno[1,2-b]indole-type CK2 inhibitors were determined using MOE software (Chemical Computing Group, Montreal, Canada). This pharmacophore model was used for database mining with the aim to identify novel scaffolds for developing new potent and selective CK2 inhibitors. Using this strategy several structures were selected by searching inside the ZINC compound database. One of the selected compounds was bikaverin (6,11-dihydroxy-3,8-dimethoxy-1-methylbenzo[b]xanthene-7,10,12-trione), a natural compound which is produced by several kinds of fungi. This compound was tested on human recombinant CK2 and turned out to be an active inhibitor with an IC50 value of 1.24 µM. View Full-Text
Keywords: CK2; cancer; indeno[1,2-b]indoles; pharmacophore; MOE; ZINC database CK2; cancer; indeno[1,2-b]indoles; pharmacophore; MOE; ZINC database
Show Figures

Figure 1

MDPI and ACS Style

Haidar, S.; Bouaziz, Z.; Marminon, C.; Laitinen, T.; Poso, A.; Le Borgne, M.; Jose, J. Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining. Pharmaceuticals 2017, 10, 8.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop